Norris Cotton Cancer Center
About Us News & Events Careers How to Help
Patient Care For Patients & Visitors For Cancer Professionals Cancer Research Clinical Trials Regional Locations
Search

James DiRenzo, Ph.D.
Associate Professor of Pharmacology of Toxicology
Scientific Co-Director of the Breast Clinical Oncology Program

Contact Information
Phone: 603-650-1794
Fax: 603-650-1129
Labphone:
Email Address: james.direnzo@dartmouth.edu
Website: http://cobweb.dartmouth.edu/cgi-bin/cgiwrap/~dms/facultydb/profile_read.pl?uid=146
Laboratory Website : http://www.dartmouth.edu/dms/pharmtox/

Postal Address
Dr. James DiRenzo
7650 Remsen
Dept. of Pharmacology and Toxicology, DMS
Hanover NH 03755

Education
University of California, San Diego School of Medicine, Ph.D. 1995

Program Membership
Cancer Mechanisms Research Program
 
Department Membership
Pharmacology & Toxicology
 
Graduate Training Program Affiliation
Pharmaclogy and Toxicology

Biography
Dr. DiRenzo received his Ph.D. from the University of California, San Diego School of Medicine in 1995. He received post-doctoral training from 1995 through 1999 in the Department of Adult Oncology at the Dana Farber Cancer Institute at Harvard. Since 1999, he has continued his studies at the Dana Farber as an Instructor in Medicine. Dr. DiRenzo joined the Department of Pharmacology and Toxicology at Dartmouth as an Assistant Professor in the summer of 2001
Our laboratory is interested in the genetic control of cellular differentiation within the mammary gland. The epithelial portion of the mammary gland is a dynamic structure that undergoes successive regenerative cycles of proliferation, acquisition of physiologic function and cell death. The death of mature terminally differentiated cells is balanced by activities of basal progenitors, which must survive developmentally regulated cell death and re-initiate proliferation during re-population of the gland. During this proliferative phase, basal progenitors execute a critical decision to either retain their proliferative capacity and de-differentiated phenotype (self-renewal) or initiate a program of cellular differentiation (commitment). A critical determinant of this decision is the expression status of a member of the p53 family of transcriptional regulators called DN-p63. DN-p63 directly opposes many of the activities of p53 by acting as a dominant negative regulator of p53-target genes. Several studies have shown that the expression of DN-p63 is required for maintenance of self-renewal within the basal progenitor lineage. Other studies have shown that repression of DN-p63 expression is required for commitment.
The major goals of our laboratory are: 1. To understand the mechanisms underlying the decision to self-renew or commit to differentiation by identifying factors which regulate transcriptional activity of the gene encoding DN-p63. Recent studies from out lab demonstrate that DN-p63 is a direct transcriptional of p53. This suggests that p53 may play a role in self-renewal by directing expression of a factor that opposes its downstream activities. 2. To understand the role of DN-p63 in the preservation of basal progenitors during developmentally regulated apoptosis. 3. To identify downstream effectors of DN-p63 that are expressed as a result of disruption of DN-p63 expression or activity, and to determine the contributions of these genes to cellular differentiation.
Selected Publications
Harmes DC, Bresnick E, Lubin EA, Watson JK, Heim KE, Curtin JC, Suskind AM, Lamb J, DiRenzo J. Positive and Negative Regulation of DN-p63 Promoter Activity by p53 and DN-p63-a Contributes to Differential Regulation of p53 Target Genes. Oncogene (In Press).
DiRenzo J, Signoretti S, Nakamura N, Rivera-Gonzalez R, Sellers W, Loda M, Brown M (2002). Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res 62 (1): 89-98.
DiRenzo J, Shang Y, Phelan S, Sif S, Myers M, Kingston R, Brown M (2000). BRG-1 is recruited to estrogen-responsive promoters and cooperates with factors involved in histone acetylation. Mol Cell Bio 20 (20): 7541-7549.
Shang Y, Hu X, DiRenzo J, Lazar M, Brown M (2000). Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103 (6): 843-852.
Kurokawa R*, DiRenzo J*, Boehm M, Sugarman J, Gloss B, Rosenfeld MG, Heyman RA, Glass CK (1994). Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding. Nature 371 (6497): 528-531 (* Co-first Authors).
Research / Lab Interests
Genetic control of self-renewal in a progenitor cell population during mammary gland differentiation.
The major goals of our laboratory are: 1. To understand the mechanisms underlying the decision to self-renew or commit to differentiation by identifying factors which regulate transcriptional activity of the gene encoding DN-p63. Recent studies from out lab demonstrate that DN-p63 is a direct transcriptional of p53. This suggests that p53 may play a role in self-renewal by directing expression of a factor that opposes its downstream activities. 2. To understand the role of DN-p63 in the preservation of basal progenitors during developmentally regulated apoptosis. 3. To identify downstream effectors of DN-p63 that are expressed as a result of disruption of DN-p63 expression or activity, and to determine the contributions of these genes to cellular differentiation.
The most reliable predictor of breast cancer risk is the length of a woman’s reproductive life, which is proportional to the number of regenerative cycles within the mammary gland. Each regenerative cycle represents an opportunity for mutations to occur, and while the protective effects of apoptosis neutralize many of these mutations, others may be harbored and propagated within the subset of self-renewing progenitors that resist developmentally regulated apoptosis. In subsequent regenerative cycles, cells bearing such mutations may give rise to daughter cells that exit the progenitor compartment but fail to complete a program of terminal differentiation resulting in a growth or survival advantage. By doing so these cells may undergo additional mutations that further relieve constraints upon their growth and allow them to progress towards malignancy. This suggests that such cells would be ideal targets for chemo-prevention and underscores the importance of understanding the nature of the mammary progenitor cell and the genetic and endocrine signals that initiate cellular differentiation.
Grants, Honors, Invited Lectures
General Motors Cancer Research Foundation Scholars Award. (January 2002-January 2004).
The V Foundation For Cancer Research Scholars Award. (August 2003-August 2005).

NCI Logo